Answers are grounded in this paper and cite their sources.
Intracutaneous botulinum toxin A mitigates gustatory sweating in Frey syndrome patients, suggesting a new standard of care.
A 58-year-old male experienced gustatory sweating on the left side of his face for 2 years following a left parotidectomy a decade prior. He was clinically diagnosed with Frey syndrome, confirmed by a starch-iodine test. To treat the condition, intracutaneous botulinum toxin A injections were administered at 1 cm intervals across the affected area. Each site received two units, with follow-up assessments at 2 weeks, 3 months, and biannually over 2 years. The treatment successfully mitigated sweating without complications, such as localized muscle weakness or skin changes. Frey syndrome, though benign, can socially impact patients due to its noticeable symptoms. Botulinum toxin A proves to be an effective treatment with minimal invasiveness and a high success rate, surpassing alternative topical therapies such as aluminum chloride and glycopyrronium bromide, which lack supporting randomized study data. Consequently, botulinum toxin A remains the preferred therapeutic approach for Frey syndrome.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: